Baird Maintains Outperform on Apellis Pharmaceuticals, Lowers Price Target to $86
Baird Maintains Outperform on Apellis Pharmaceuticals, Lowers Price Target to $86
Baird維持對Apellis Pharmaceuticals的跑贏市場評級，將目標價調降至86美元。
Baird analyst Colleen Kusy maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Outperform and lowers the price target from $100 to $86.
貝爾德分析師Colleen Kusy 維持Apellis Pharmaceuticals (納斯達克:apellis pharmaceuticals)的表現良好評級，並從100美元調降目標股價至86美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。